Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision birth control test using hormone and genetic data to personalize contraceptive selection; $2.65M from Lux Capital and M13 addressing trial-and-error that leaves millions on wrong contraceptives.
adyn is a precision medicine company developing personalized birth control solutions through at-home testing kits that analyze hormone levels and genetic risk factors — enabling individuals to choose hormonal contraceptives based on their own biology rather than trial-and-error, addressing a gap where most people cycle through multiple birth control options over years to find what works without causing intolerable side effects. Founded in 2019 and a Y Combinator graduate, adyn raised $2.65 million in seed funding co-led by Lux Capital and M13, with the Birth Control Optimization Test positioned as the first biology-based test for contraceptive personalization.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.